Antiviral therapies: focus on hepatitis B reverse transcriptase
about
Current and future antiviral drug therapies of hepatitis B chronic infectionThe hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymesMolecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia.A cutting-edge view on the current state of antiviral drug development.4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanismsModeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction.Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patientsLarge-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase.Serum IL-21 levels associated with chronic hepatitis B and hepatitis B-related liver failure.Molecular characterisation of hepatitis B virus in the resident Chinese population in Panama City.Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview.Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells.Resistance mutations of hepatitis B virus in entecavir-refractory patients.
P2860
Q28084820-1868E93D-B8FF-4400-BC83-4326A457FE65Q28485228-E994A021-BAB5-4D67-A2C7-D315585ACD82Q33883921-288B492A-96FA-4147-863C-6D7FADED57EDQ34036018-824C9519-8D64-4CD9-A513-8457819576D5Q34107343-0459C38F-73E5-4778-BAD1-E26E04642C43Q36120901-F4FA420D-F958-48DB-A9CC-CE30F851F12CQ36244591-F6976A63-1F84-4D2C-B072-206112999A60Q37200146-66FC9CC5-2B89-472B-BDEA-64AB4514A6E7Q37335626-587BFF9B-4C2F-4186-9267-0348B3173129Q37409858-528A30AC-2D09-4296-8A50-345FF9409F1BQ37644005-7548A29C-63B0-4752-9868-E9B72C6D213FQ37661691-5CE78CE6-BA2C-44AC-B984-70676242A930Q37674915-E552505B-65A0-4FA5-BF11-CE2128B7C71AQ38447283-F7D2DFB9-9791-4C35-A9F1-EE4317097C74Q38867984-362842EF-B229-4C15-8E21-C69106615AF7Q47548606-F8249914-CA8B-49E1-AE84-109869BA1203Q52579709-1A7FCFE4-7E8C-4049-AB44-DEFFEE6066FFQ52699085-95FB4D69-693A-47F5-9B49-B26EDCF581DA
P2860
Antiviral therapies: focus on hepatitis B reverse transcriptase
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Antiviral therapies: focus on hepatitis B reverse transcriptase
@ast
Antiviral therapies: focus on hepatitis B reverse transcriptase
@en
type
label
Antiviral therapies: focus on hepatitis B reverse transcriptase
@ast
Antiviral therapies: focus on hepatitis B reverse transcriptase
@en
prefLabel
Antiviral therapies: focus on hepatitis B reverse transcriptase
@ast
Antiviral therapies: focus on hepatitis B reverse transcriptase
@en
P2093
P2860
P1476
Antiviral therapies: focus on hepatitis B reverse transcriptase
@en
P2093
Atsuko Hachiya
Eleftherios Michailidis
Soo-Ok Kim
Sun Pyo Hong
Wangdon Yoo
William R Folk
P2860
P304
P356
10.1016/J.BIOCEL.2012.04.006
P577
2012-04-16T00:00:00Z